Please assess the completion status of the following clinical trial:

Trial Title: A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma~* Metastatic disease or locally advanced, unresectable disease~* Disease progression during or within 4 months after the last dose of the first-line therapy (platinum/fluoropyrimidine doublet with or without anthracycline)~* Organs are functioning well (liver, kidney, blood)~* Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1~Exclusion Criteria:~* First line chemotherapy for metastatic gastric cancer other than platinum/fluoropyrimidine doublet with or without anthracycline~* Previous systemic therapy with other anti-angiogenic drugs~* Uncontrolled high blood pressure~* Symptomatic or poorly controlled heart disease or had a heart attack or stroke within the last 6 month~* Evidence of central nervous system (CNS) metastasis at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel (Type: EXPERIMENTAL): Ramucirumab (IMC-1211B) DP and Paclitaxel
- Placebo and Paclitaxel (Type: PLACEBO_COMPARATOR): Placebo and Paclitaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).